Enzymotec Granted Patent in Singapore for INFAT
11 Aug 2015 --- Enzymotec has announced that INFAT, the innovative ingredient that is marketed by Advanced Lipids, a joint venture of AAK and Enzymotec, was granted a patent by the Singaporean Patent and Trademark Office for uses related to promoting development of beneficial gut flora and reducing infant crying.
INFAT, a clinically proven fat ingredient (OPO) developed specifically for infant formula, incorporates essential qualities of mothers’ milk fat – enabling an ideal alternative when breast milk is not available. INFAT closely mimics the composition, structure and nutritional value of natural fat in breast milk, for proper infant health, development and comfort.
“This patent joins our wide IP portfolio which constitutes the basis of the strategy to lead the market through innovation and to provide a clear edge to INFAT's customers", says Dr. Fabiana Bar-Yoseph of Enzymotec Infant Nutrition R&D. "The patent covers the use of lipid composition, comprising a mixture of synthetic triglycerides with 15-55% palmitic for inducing a beneficiary effect on the immune system by promoting development of beneficial gut flora and for reducing the frequency and duration of infant crying" concludes Dr. Bar-Yoseph.
This granted patent is supported by published clinical data demonstrating that infants fed with formula containing INFAT develop similar variety of beneficial gut bacteria as breastfed babies. This promotes good health, growth, and ability to prevent infections. In addition, clinical data shows that babies nourished by formula containing INFAT cry less and for shorter duration in comparison to babies fed with regular infant formula.
